曲美他嗪对高血压病伴阵发性房颤患者左房内径及C反应蛋白的影响及其机制

目的探讨曲美他嗪治疗高血压病伴阵发性房颤的临床疗效及对左房内径、c反应蛋白的影响及其机制。方法将52例高血压病伴阵发性房颤患者随机分为常规治疗组（对照组）和加用曲美他嗪组，每组26例，均服药12个月，观察两组治疗前后临床疗效、左心房内径及血清C反应蛋白水平变化。结果两组间一般资料相似，随访12个月后，曲美他嗪组窦性心律维持率大于常规治疗组，但两者无统计学意义（P〉0．05）；而曲美他嗪组左房内径及血清C反应蛋白水平显著小于常规治疗组（P〈0．05）。结论曲美他嗪能改善心肌代谢，抑制炎症反应及左房重构，对预防阵发性房颤的复发有一定作用。

Effect and mechanism of trimetazidine on left atrial diameter and C-reactive protein in hypertensive patients with paroxysmal atrial fibrillation

Objective To discuss the clinical curative effect of trinaetazidine on left atrial diameter（LAD ） and C-reactive pro- tein （CRP） in hypertensive patients with paroxysmal atrial fibrillation （PAF）. Methods 52 hypertensive patients with PAF were randomly assigned to either conventional treatment group（control group, n=26） or study group with trinaetazidine（n=26） with treatment for 12 maonths. The clinical curative effect and the changes of LAD and CRP were observed. Results The basic clinical data were sinai- lax among the 2 groups. 12 months＇ follow-up,the maintenance rate of sinus rhythm in trimetazidine group was greater than that in control group ,without statistical significance （P 〉 0.05）.LAD and the level of CRP in trimetazidine group were significant less than that in control group（P 〈 0.05）. Conclusions The treatment with trimetazidine could prevent recurrence of paroxysmal atrial fibrillation though improving myocardial metabolism,inhibiting inflammatory reactian and left atrium remodeling.